DrugPatentWatch Database Preview
Drugs in Development Information for PRX-03140
» See Plans and Pricing
What is the drug development status for PRX-03140?
PRX-03140 is an investigational drug.
There have been 21 clinical trials for PRX-03140.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2005.
The most common disease conditions in clinical trials are Fabry Disease, Disease, and Alzheimer Disease. The leading clinical trial sponsors are Epix Pharmaceuticals, Inc., Protalix, and Presbyopia Therapies, LLC.
Summary for PRX-03140
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 232 |
| WIPO Patent Applications | 187 |
| Japanese Patent Applications | 92 |
| Clinical Trial Progress | Phase 3 (2005-08-01) |
| Vendors | 3 |
Recent Clinical Trials for PRX-03140
| Title | Sponsor | Phase |
|---|---|---|
| Prodrug PRX-P4-003 Microdose Study | Praxis Bioresearch, LLC | Early Phase 1 |
| INDUCTION CHEMO-IMMUNOTHERAPY FOLLOWED BY CONSOLIDATION WITH REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANT IN ADVANCED STAGE MATURE NON-ANAPLASTIC T-CELL OR NK LYMPHOMA/LEUKEMIA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS | University of Alabama at Birmingham | Early Phase 1 |
| INDUCTION CHEMO-IMMUNOTHERAPY FOLLOWED BY CONSOLIDATION WITH REDUCED TOXICITY CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANT IN ADVANCED STAGE MATURE NON-ANAPLASTIC T-CELL OR NK LYMPHOMA/LEUKEMIA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS | New York Medical College | Early Phase 1 |
Clinical Trial Summary for PRX-03140
Top disease conditions for PRX-03140
Top clinical trial sponsors for PRX-03140
US Patents for PRX-03140
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
